SCHEMBL14901971

SCHEMBL14901971

COC(=O)c1cc(C)c(-c2ccc(C)cc2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.45
MAPT P10636 3/20 0.44
ALPL P05186 2/20 0.44
RAB9A P51151 2/20 0.44
CYP46A1 Q9Y6A2 1/20 0.44
POLB P06746 1/20 0.44
SLC2A1 P11166 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 1/20 0.43
LCK P06239 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14889656 0.88 KDM4E (0.52) MAPK1MAPTALPLRAB9ASLC2A1
SCHEMBL14901970 0.83 MAPK1 (0.41) MAPK1MAPTSLC2A1ALDH1A1HSD17B10
SCHEMBL14889881 0.80 MAPK1 (0.42) MAPK1MAPTSLC2A1ALDH1A1HSD17B10
SCHEMBL18825226 0.78 MAPK1 (0.53) MAPK1MAPTALDH1A1HSD17B10LCK
SCHEMBL14210410 0.76 FDPS (0.48) MAPK1MAPTALPLRAB9ACYP46A1
SCHEMBL19835341 0.76 SLC6A3 (0.51) MAPK1MAPTRAB9AALDH1A1HSD17B10
SCHEMBL14901969 0.75 LIPE (0.39) MAPK1LCKKDM4EL3MBTL1
SCHEMBL28241571 0.75 GABRA1 (0.50) MAPK1MAPTALDH1A1HSD17B10LCK
SCHEMBL14022401 0.75 RAB9A (0.50) MAPK1MAPTALPLRAB9APOLB
SCHEMBL21284412 0.75 SLC6A4 (0.50) MAPK1MAPTRAB9AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346825-B2 Fused bicyclic oxazolidinone CETP inhibitor MERCK SHARP & DOHME CORP. (US) 2016-05-24 US disclosed
US-20140378493-A1 Fused Bicyclic Oxazolidinone CETP Inhibitor MERCK SHARP & DOHME LLC 2014-12-25 US disclosed
US-8871738-B2 Fused bicyclic oxazolidinone CETP inhibitor MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-20130109649-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR MERCK SHARP & DOHME LLC 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378493-A1 Fused Bicyclic Oxazolidinone CETP Inhibitor CETP, MTTP, APOB MAPK1 3394/4885MAPT 2668/4885ALPL 614/4885
US-20130109649-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR CETP, MTTP, APOB MAPK1 3394/4885MAPT 2668/4885ALPL 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.